摘要
为了进一步规范器官移植病理学临床技术操作,中华医学会器官移植学分会组织器官移植专家和移植病理学专家,从移植心脏心内膜心肌活组织检查的临床操作规范、移植心脏排斥反应的病理学诊断临床技术操作规范、移植心脏的心肌缺血损伤的病理学诊断临床技术操作规范、移植心脏血管病的病理学诊断临床技术操作规范、移植后淋巴组织增生性疾病的病理学诊断临床技术操作规范、移植心脏心内膜心肌活组织检查病理报告的基本内容规范、移植心脏心内膜心肌活组织检查病理学诊断的难点与局限性、移植心脏病理学相关的其它临床技术操作规范等方面,制定器官移植病理学临床技术操作规范(2019版)之移植心脏病理学临床技术操作规范。
引文
[1]黄洁,杨跃进,尹栋,等.心内膜心肌活检439例次的安全性分析[J].中华心血管病杂志,2010,38(1):43-46.DOI:10.3760/cma.j.issn.0253-3758.2010.01.013.HUANG J,YANG YJ,YIN D,et al.Safety analyses from 439 patients underwent endomyocardial biopsy[J].Chin J Cardiol,2010,38(1):43-46.DOI:10.3760/cma.j.issn.0253-3758.2010.01.013.
[2]FIORELLI AI,BENVENUTI L,AIELO V,et al.Comparative analysis of the complications of 5347endomyocardial biopsies applied to patients after heart transplantation and with cardiomyopathies:a singlecenter study[J].Transplant Proc,2012,44(8):2473-2478.DOI:10.1016/j.transproceed.2012.07.023.
[3]LAMPERT BC,TEUTEBERG JJ,SHULLO MA,et al.Cost-effectiveness of routine surveillance endomyocardial biopsy after 12 months post-heart transplantation[J].Circ Heart Fail,2014,7(5):807-813.DOI:10.1161/CIRCHEARTFAILURE.114.001199.
[4]LUND LH,EDWARDS LB,KUCHERYAVAYA AY,et al.The Registry of the International Society for Heart and Lung Transplantation:thirty-second official adult heart transplantation report--2015;focus theme:early graft failure[J].J Heart Lung Transplant,2015,34(10):1244-1254.DOI:10.1016/j.healun.2015.08.003.
[5]LI L,DUAN XJ,WANG HY,et al.Acute cellular rejection and antibody-mediated rejection in endomyocardial biopsy after heart transplantation:a retrospective study from a single medical center[J].Int J Clin Exp Pathol,2017,10(4):4772-4779.
[6]BERRY GJ,BURKE MM,ANDERSEN C,et al.The 2013 International Society for Heart and Lung Transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation[J].J Heart Lung Transplant,2013,32(12):1147-1162.DOI:10.1016/j.healun.2013.08.011.
[7]STEWART S,WINTERS GL,FISHBEIN MC,et al.Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection[J].JHeart Lung Transplant,2005,24(11):1710-1720.
[8]LEONE O,VEINOT JP,ANGELINI A,et al.2011consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology[J].Cardiovasc Pathol,2012,21(4):245-274.DOI:10.1016/j.carpath.2011.10.001.
[9]HAAS M,SIS B,RACUSEN LC,et al.Banff 2013meeting report:inclusion of C4d-negative antibodymediated rejection and antibody-associated arterial lesions[J].Am J Transplant,2014,14(2):272-283.DOI:10.1111/ajt.12590.
[10]COLVIN MM,COOK JL,CHANG P,et al.Antibodymediated rejection in cardiac transplantation:emerging knowledge in diagnosis and management:a scientific statement from the American Heart Association[J].Circulation,2015,131(18):1608-1639.DOI:10.1161/CIR.0000000000000093.
[11]MILLER DV,KFOURY AG.“Mixed”rejection in heart transplantation[M]//LEONE O,ANGELINI A,BRUNEVAL P,et al.The pathology of cardiac transplantation:clinical and pathological perspective.Switzerland:Springer International Publishing,2016:243-250.
[12]TAN CD,BALDWIN WM 3RD,RODRIGUEZ ER.Update on cardiac transplantation pathology[J].Arch Pathol Lab Med,2007,131(8):1169-1191.
[13]JOSHI A,MASEK MA,BROWN BW JR,et al."Quilty"revisited:a 10-year perspective[J].Hum Pathol,1995,26(5):547-557.DOI:10.1016/0046-8177(95)90252-X.
[14]FYFE B,LOH E,WINTERS GL,et al.Heart transplantation-associated perioperative ischemic myocardial injury.morphological features and clinical significance[J].Circulation,1996,93(6):1133-1140.DOI:10.1161/01.CIR.93.6.1133.
[15]LU WH,PALATNIK K,FISHBEIN GA,et al.Diverse morphologic manifestations of cardiac allograft vasculopathy:a pathologic study of 64 allograft hearts[J].J Heart Lung Transplant,2011,30(9):1044-1050.DOI:10.1016/j.healun.2011.04.008.
[16]MEHRA MR,CRESPO-LEIRO MG,DIPCHAND A,et al.International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010[J].J Heart Lung Transplant,2010,29(7):717-727.DOI:10.1016/j.healun.2010.05.017.
[17]SABATTINI E,BACCI F,SAGRAMOSO C,et al.WHOclassification of tumours of haematopoietic and lymphoid tissues in 2008:an overview[J].Pathologica,2010,102(3):83-87.
[18]CRESPO-LEIRO MG,ZUCKERMANN A,BARA C,et al.Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study(CARGO II)[J].Transplantation,2012,94(11):1172-1177.DOI:10.1097/TP.0b013e31826e19e2.
[19]ANGELINI A,ANDERSEN CB,BARTOLONI G,et al.A web-based pilot study of inter-pathologist reproducibility using the ISHLT 2004 working formulation for biopsy diagnosis of cardiac allograft rejection:the European experience[J].J Heart Lung Transplant,2011,30(11):1214-1220.DOI:10.1016/j.healun.2011.05.011.
[20]COOPER LT,BAUGHMAN KL,FELDMAN AM,et al.The role of endomyocardial biopsy in the management of cardiovascular disease:a scientific statement from the American Heart Association,the American College of Cardiology,and the European Society of Cardiology[J].Circulation,2007,116(19):2216-2233.DOI:10.1161/circulationaha.107.186093.
[21]STONE JR,BASSO C,BAANDRUP UT,et al.Recommendations for processing cardiovascular surgical pathology specimens:a consensus statement from the Standards and Definitions Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology[J].Cardiovasc Pathol,2012,21(1):2-16.DOI:10.1016/j.carpath.2011.01.001.
[22]BASSO C,BURKE M,FORNES P,et al.Guidelines for autopsy investigation of sudden cardiac death[J].Virchows Arch,2008,452(1):11-18.DOI:10.1007/s00428-007-0505-5.